Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. The company’s programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product in clinical development is bremelanotide for the treatment of female sexual dysfunction (FSD). In addition, the company has drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, dermatologic diseases and inflammatory diseases. Drug Development Programs The company has the following drug development programs under development: Bremelanotide, an on-demand subcutaneous injectable peptide melanocortin receptor agonist, for treatment of FSD. Bremelanotide is scheduled to start Phase 3 clinical trials in 2014; Melanocortin receptor-based compounds for treatment of obesity, under development by AstraZeneca AB (AstraZeneca) pursuant to the company’s research collaboration and license agreement; PL-3994, a peptide mimetic natriuretic peptide receptor A (NPR-A) agonist, for treatment of cardiovascular and pulmonary indications; and Melanocortin receptor-1 agonist (MC1R) peptides, for treatment of dermatologic and inflammatory disease indications. Strategy Main elements of the company’s business strategy include the following: using technology and expertise to develop and commercialize therapeutic products; entering into alliances and partnerships with pharmaceutical companies to facilitate the development, manufacture, marketing, sale and distribution of product candidates that the company is developing; and partially funding product development programs with the cash flow generated from license agreement with AstraZeneca and any other companies. Patents and Proprietary Information The company owns two issued United States patents claiming the bremelanotide substance; issued patents claiming the bremelanotide substance in Japan, Mexico, Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Ireland, Korea, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom, Italy, Australia, New Zealand, Brazil and Canada. The company owns an issued patent in the United States and New Zealand claiming an alternative class of melanocortin receptor-specific peptides for treatment of sexual dysfunction and patent applications on the same class are pending in the United States, Australia, Brazil, Canada, China, India, Israel, Japan, Korea, Mexico and South Africa and before the European and Eurasian patent offices. The presumptive term of the patent issued in the United States is until 2029. The company also owns patent applications for a second class of alternative melanocortin receptor-specific peptides for treatment of sexual dysfunction which are pending in the United States, Australia, Brazil, Canada, China, India, Israel, Japan, Korea, Mexico, New Zealand and South Africa and before the European and Eurasian patent offices. The company owns an issued United States patent claiming a narrow class of highly selective MC1R agonist peptides for treatment of inflammation-related diseases and disorders and related indications, and patent applications on two broader classes of highly selective MC1R agonist peptides which are pending in the United States, Australia, Brazil, Canada, China, India, Israel, Japan, Korea, Mexico and South Africa and before the European and Eurasian patent offices. The presumptive term of the patent issued in the United States is until 2030. The company owns an issued United States patent claiming the PL-3994 substance and other natriuretic peptide receptor agonist compounds that it has developed and an issued United States patent claiming a precursor molecule to the PL-3994 substance, both of which have a term until 2027. Corresponding patents have issued in the European patent office, South Africa, Russia, France, Germany, Mexico, Philippines and Colombia, and applications claiming the PL-3994 substance and other compounds, including precursor molecules, are pending in Australia, Brazil, Canada, China, India, Israel, Japan and Korea. The company additionally has 27 issued United States patents on melanocortin receptor specific peptides and small molecules. Research and development The company’s research and development expenses included $10.5 million for fiscal 2013. History Palatin Technologies, Inc. was founded in 1986. The company was incorporated in Delaware in 1986.
palatin technologies inc (PTN:NYSE Amex)
4B Cedar Brook Drive
Cedar Brook Corporate Center
Cranbury, NJ 08512
|No competitor information is available for PTN.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Post a JobJobs
- San Francisco, CA | SmartrecruitersPosted: Apr 09
- Washington, DC | DC BarPosted: Apr 09
- Washington, DC | DC BarPosted: Apr 09
- Carlinville, IL | KarmakPosted: Mar 25
Sponsored Financial Commentaries
To contact PALATIN TECHNOLOGIES INC, please visit www.palatin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.